Physician profile
Caroline C Dewitt
NPI 1518957547
$4,941.16
in general payments reported to CMS, 2019-2025
16 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $621 · 2021: $393 · 2022: $652 · 2023: $751 · 2024: $770 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $23.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.00 |
| Education | $23.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,552.70 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $899.32 | 2019-2025 | Biktarvy, Veklury |
| Abbvie INC. | $688.76 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Cumberland Pharmaceuticals, INC. | $338.98 | 2019-2025 | Vibativ |
| Melinta Therapeutics, LLC | $299.22 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Paratek Pharmaceuticals, INC. | $287.11 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $251.95 | 2019-2025 | Zerbaxa, Prevymis, Dificid |
| Allergan, INC. | $166.61 | 2019-2020 | |
| Janssen Biotech, INC. | $144.39 | 2019-2023 | Symtuza |
| Insmed, INC. | $93.99 | 2019-2022 | |
| Cipla USA INC. | $69.48 | 2019 | |
| Shionogi INC | $65.11 | 2020-2024 | Fetroja |
| Nabriva Therapeutics, Plc | $25.31 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.01 | 2022 | |
| Octapharma USA, INC. | $20.00 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $18.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.